ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

285
Analysis
Health CareHong Kong
Sino Biopharmaceutical Limited, through its subsidiaries, researches, develops, produces, and sells biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis.
more
27 Apr 2020 15:59

HK Connect Weekly: Tencent, Sino Biopharm, CSPC, SMIC

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound  Hong Kong...

Logo
358 Views
Share
bullishKingsoft Cloud
26 Apr 2020 12:44

ECM Weekly (26 Apr 2020) - Kingsoft Cloud, WeDoctor, Akesobio, Kotak Mahindra Bank

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Akeso...

Share
21 Apr 2020 21:49

Hansoh Pharma Placement - Good Stock but Valuation and No Lack of Cash Makes It Appear Opportunistic

Hansoh Pharmaceutical (3692 HK) aims to raise up to US$450m to funds its R&D and general working capital requirements. The company was listed...

Logo
502 Views
Share
20 Apr 2020 20:39

Sino Biopharm (中国生物制药) Placement - Not a Big Deal, Still a Good Company but Relatively Expensive

A shareholder of Sino Biopharmaceutical (1177 HK) is looking to sell about US$297m worth of shares in an accelerated block trade.In this note, we...

Share
14 Apr 2020 14:04

Akesobio IPO: Valuation Insights

Akeso Biopharma Inc (9926 HK) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology...

Logo
550 Views
Share
x